Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD trial of eribulin + trastuzumab + pertuzumab versus taxane + trastuzumab + pertuzumab in HER2-positive advanced or recurrent breast cancer
jRCTs021180027Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eribulin, trastuzumab, pertuzumab, paclitaxel and docetaxel in breast cancer (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs021180027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180027.